

Haematologica
HAEMATOL/2016/153189
Version 3

miR-125b and miR-532-3p predict efficiency of the rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A FILO study.

Anne-Laure Gagez, Isabelle Duroux-Richard, Stéphane Leprêtre, Frédérique Orsini-Piocelle, Rémi Letestu, Sophie De Guibert, Edouard Tuillon, Véronique Leblond, Olfa Khalifa, Valérie Gouilleux-Gruart, Anne Banos, Olivier Tournilhac, Jehan Dupuis, Christian Jorgensen, Guillaume Cartron, and Florence Apparailly

Disclosures: This work is supported by a public grant overseen by the French National Research Agency (ANR) as part of the “Investissements d’Avenir” program (reference Labex MAblmprove: ANR-10-LABX-53-01), the INSERM and the university of Montpellier. This study was funded by FILO group and F. Hoffman-La Roche Ltd (Basel, Switzerland).

Authors: Disclosure of Conflicts of Interest. Consultancy within the past two years: Guillaume Cartron (GC), Remi Letestu (RL). Honoraria directly received from an entity: Guillaume Cartron (GC) and Remi Letestu (RL). All other authors have no conflicts of interest.

Contributions: Designed research: GC, FA, IDR Performed research: ALG, GC, FA, IDR, OK, ET, RL, VGG Collected data: ALG, GC, ET, RL, VGG, IDR, SL, FOP, SDG, VL, AB, OT, JD Analyzed and interpreted data: ALG, GC, FA, IDR Performed statistical analysis: ALG, IDR Wrote/reviewed the manuscript: ALG, GC, FA, IDR Approved manuscript: ALG, IDR, SL, FOP, RL, SDG, ET, VL, OK, VGG, AB, OT, JD, CJ, GC, FA